Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous FMT in Infants Treated With Antibiotics
NCT06609980Phase 1Recruiting
- Sponsor
- Rutgers University
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous fecal microbiota transplantation in Antibiotic-induced dysbiosis (2 arms), sponsored by Rutgers University. Primary endpoint: Safety of autologous FMT at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
autologous fecal microbiota transplantation
03
Conditions
Antibiotic-induced dysbiosis
Beyond the preview
Go deeper on NCT06609980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609980.